Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches

Several melanoma cell subpopulations with tumor-initiating and/or tumor-maintaining properties exist that may contribute to chemoresistance and tumor recurrence after standard therapies. One of these subpopulations expresses a B-cell marker, CD20. In a small pilot trial, we showed that a subset of S...

Descripción completa

Detalles Bibliográficos
Autores principales: Maurer, Margarita, Somasundaram, Rajasekharan, Herlyn, Meenhard, Wagner, Stephan N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518536/
https://www.ncbi.nlm.nih.gov/pubmed/23243627
http://dx.doi.org/10.4161/onci.21357
_version_ 1782252571660910592
author Maurer, Margarita
Somasundaram, Rajasekharan
Herlyn, Meenhard
Wagner, Stephan N.
author_facet Maurer, Margarita
Somasundaram, Rajasekharan
Herlyn, Meenhard
Wagner, Stephan N.
author_sort Maurer, Margarita
collection PubMed
description Several melanoma cell subpopulations with tumor-initiating and/or tumor-maintaining properties exist that may contribute to chemoresistance and tumor recurrence after standard therapies. One of these subpopulations expresses a B-cell marker, CD20. In a small pilot trial, we showed that a subset of Stage IV melanoma patients may potentially benefit from an adjuvant treatment using the anti-CD20 antibody rituximab.
format Online
Article
Text
id pubmed-3518536
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-35185362012-12-14 Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches Maurer, Margarita Somasundaram, Rajasekharan Herlyn, Meenhard Wagner, Stephan N. Oncoimmunology Author's View Several melanoma cell subpopulations with tumor-initiating and/or tumor-maintaining properties exist that may contribute to chemoresistance and tumor recurrence after standard therapies. One of these subpopulations expresses a B-cell marker, CD20. In a small pilot trial, we showed that a subset of Stage IV melanoma patients may potentially benefit from an adjuvant treatment using the anti-CD20 antibody rituximab. Landes Bioscience 2012-11-01 /pmc/articles/PMC3518536/ /pubmed/23243627 http://dx.doi.org/10.4161/onci.21357 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Maurer, Margarita
Somasundaram, Rajasekharan
Herlyn, Meenhard
Wagner, Stephan N.
Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches
title Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches
title_full Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches
title_fullStr Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches
title_full_unstemmed Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches
title_short Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches
title_sort immunotargeting of tumor subpopulations in melanoma patients: a paradigm shift in therapy approaches
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518536/
https://www.ncbi.nlm.nih.gov/pubmed/23243627
http://dx.doi.org/10.4161/onci.21357
work_keys_str_mv AT maurermargarita immunotargetingoftumorsubpopulationsinmelanomapatientsaparadigmshiftintherapyapproaches
AT somasundaramrajasekharan immunotargetingoftumorsubpopulationsinmelanomapatientsaparadigmshiftintherapyapproaches
AT herlynmeenhard immunotargetingoftumorsubpopulationsinmelanomapatientsaparadigmshiftintherapyapproaches
AT wagnerstephann immunotargetingoftumorsubpopulationsinmelanomapatientsaparadigmshiftintherapyapproaches

Ejemplares similares